Leerink Partnrs Has Optimistic Outlook of HALO Q4 Earnings

Halozyme Therapeutics, Inc. (NASDAQ:HALO) – Equities researchers at Leerink Partnrs lifted their Q4 2025 earnings estimates for Halozyme Therapeutics in a research note issued to investors on Tuesday, February 18th. Leerink Partnrs analyst D. Risinger now expects that the biopharmaceutical company will post earnings of $1.66 per share for the quarter, up from their prior estimate of $1.57. The consensus estimate for Halozyme Therapeutics’ current full-year earnings is $4.72 per share.

Other equities analysts have also recently issued reports about the company. HC Wainwright raised their price objective on Halozyme Therapeutics from $70.00 to $72.00 and gave the company a “buy” rating in a research note on Wednesday. Wells Fargo & Company decreased their price objective on Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating for the company in a report on Monday, January 13th. JMP Securities lifted their price objective on Halozyme Therapeutics from $72.00 to $73.00 and gave the stock a “market outperform” rating in a report on Friday, November 1st. Benchmark reissued a “buy” rating and issued a $75.00 price objective on shares of Halozyme Therapeutics in a report on Thursday. Finally, Piper Sandler lifted their price objective on Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a “neutral” rating in a report on Friday, January 10th. Four equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $62.78.

Halozyme Therapeutics Stock Performance

NASDAQ:HALO opened at $57.75 on Friday. The company has a market capitalization of $7.11 billion, a PE ratio of 16.84, a P/E/G ratio of 0.44 and a beta of 1.25. Halozyme Therapeutics has a fifty-two week low of $37.73 and a fifty-two week high of $65.53. The company has a 50 day simple moving average of $53.46 and a two-hundred day simple moving average of $54.62. The company has a debt-to-equity ratio of 4.14, a quick ratio of 9.15 and a current ratio of 7.80.

Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings data on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share for the quarter, topping the consensus estimate of $1.17 by $0.02. The business had revenue of $298.01 million during the quarter, compared to analysts’ expectations of $285.74 million. Halozyme Therapeutics had a net margin of 43.74% and a return on equity of 157.78%.

Hedge Funds Weigh In On Halozyme Therapeutics

A number of large investors have recently bought and sold shares of HALO. CWM LLC increased its position in Halozyme Therapeutics by 77.5% during the 3rd quarter. CWM LLC now owns 1,530 shares of the biopharmaceutical company’s stock valued at $88,000 after buying an additional 668 shares in the last quarter. Creative Planning raised its holdings in Halozyme Therapeutics by 25.6% in the 3rd quarter. Creative Planning now owns 46,834 shares of the biopharmaceutical company’s stock worth $2,681,000 after purchasing an additional 9,543 shares during the period. Raymond James & Associates raised its holdings in shares of Halozyme Therapeutics by 87.1% during the third quarter. Raymond James & Associates now owns 273,591 shares of the biopharmaceutical company’s stock valued at $15,660,000 after acquiring an additional 127,330 shares during the last quarter. Private Advisor Group LLC raised its holdings in shares of Halozyme Therapeutics by 6.2% during the third quarter. Private Advisor Group LLC now owns 24,163 shares of the biopharmaceutical company’s stock valued at $1,383,000 after acquiring an additional 1,410 shares during the last quarter. Finally, International Assets Investment Management LLC increased its holdings in shares of Halozyme Therapeutics by 5,623.9% in the third quarter. International Assets Investment Management LLC now owns 36,576 shares of the biopharmaceutical company’s stock valued at $20,940,000 after purchasing an additional 35,937 shares during the last quarter. Hedge funds and other institutional investors own 97.79% of the company’s stock.

Insider Transactions at Halozyme Therapeutics

In other news, Director Jeffrey William Henderson sold 5,000 shares of Halozyme Therapeutics stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $56.30, for a total value of $281,500.00. Following the completion of the transaction, the director now owns 38,611 shares in the company, valued at approximately $2,173,799.30. The trade was a 11.46 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 2.40% of the company’s stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.